Literature DB >> 14647204

A second chance for hormone replacement therapy?

Vicki Brower.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14647204      PMCID： PMC1326430          DOI： 10.1038/sj.embor.7400043

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  12 in total

1.  Impact of progestins on estradiol potentiation of the glutamate calcium response.

Authors:  Jon Nilsen; Roberta Diaz Brinton
Journal:  Neuroreport       Date:  2002-05-07       Impact factor: 1.837

2.  Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate.

Authors:  Jon Nilsen; Roberta Diaz Brinton
Journal:  Endocrinology       Date:  2002-01       Impact factor: 4.736

3.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.

Authors:  Peter P Zandi; Michelle C Carlson; Brenda L Plassman; Kathleen A Welsh-Bohmer; Lawrence S Mayer; David C Steffens; John C S Breitner
Journal:  JAMA       Date:  2002-11-06       Impact factor: 56.272

4.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

5.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

6.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

7.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

8.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling.

Authors:  Jon Nilsen; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

10.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321
View more
  3 in total

1.  A cause without a disease.

Authors:  Holger Breithaupt
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

2.  Hormone therapy for the ageing. Despite the negative results of recent trials, hormone replacement therapy retains enticing promises for the elderly.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2004-10       Impact factor: 8.807

3.  One hundred years of hormones.

Authors:  Jamshed R Tata
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.